首页> 外文期刊>Transfusion: The Journal of the American Association of Blood Banks >Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.
【24h】

Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.

机译:同种异体外周血祖细胞移植前存在严重ABO失配的供体型红细胞输注的安全性和影响。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Changes within the ABO system are regularly observed phenomena in allogeneic bone marrow transplantation (BMT) and peripheral blood progenitor cell transplantation (PBPCT). Major ABO mismatch can lead to different clinical problems including acute hemolysis after infusion of the allograft, delay of red blood cell (RBC) engraftment, or even manifestation of pure red cell aplasia (PRCA). STUDY DESIGN AND METHODS: This retrospective study demonstrates the safety and the impact of donor-type RBC transfusion before allogeneic PBPCT in major ABO settings as routinely performed at our transplantation unit. This study reports on transfusion of mismatched RBCs at the end of the conditioning period in 35 patients who underwent allogeneic PBPCT, which led to a decrease in isoagglutinin titers in most cases. RESULTS: A decrease of isoagglutinin titer after donor-type RBC transfusion can significantly reduce the demand of RBC transfusion between transplantation and Day +30 (p = 0.003). Interestingly, patients who developed PRCA were not observed, a complication being regularly documented by other groups. CONCLUSION: A decrease of isoagglutinin titers by in vivo immunoadsorption before allogeneic PBPCT does not only lack severe complication but also leads to a reduction in demand of RBC transfusion after engraftment and may reduce the incidence of PRCA in these patients.
机译:背景:ABO系统内的变化是同种异体骨髓移植(BMT)和外周血祖细胞移植(PBPCT)中经常观察到的现象。严重的ABO失配可导致不同的临床问题,包括同种异体输注后的急性溶血,红细胞(RBC)植入的延迟,甚至纯红细胞发育不全(PRCA)的表现。研究设计和方法:这项回顾性研究证明了在异种PBPCT之前在主要ABO设置中同种异体PBPCT输血的安全性和输注RBC的影响,这是在我们的移植部门常规进行的。这项研究报告了在35名接受同种异体PBPCT的患者中,在适应期结束时输注了不匹配的RBC,这在大多数情况下导致异凝集素滴度的降低。结果:供体型RBC输注后异凝集素滴度的降低可显着降低移植与第+30天之间的RBC输注需求(p = 0.003)。有趣的是,未观察到发生PRCA的患者,其他组定期记录并发症。结论:同种异体PBPCT之前体内免疫吸附可降低异凝集素效价,这不仅缺乏严重的并发症,而且降低了植入后RBC输血的需求,并可能降低这些患者PRCA的发生率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号